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Peripheral administration of lactate produces
antidepressant-like effects
A Carrard1,4, M Elsayed2,4, M Margineanu3, B Boury-Jamot1,2, L Fragnière1, EM Meylan1, J-M Petit1,2, H Fiumelli3, PJ Magistretti1,2,3,5 and
J-L Martin1,5
In addition to its role as metabolic substrate that can sustain neuronal function and viability, emerging evidence supports a role for
L-lactate as an intercellular signaling molecule involved in synaptic plasticity. Clinical and basic research studies have shown that
major depression and chronic stress are associated with alterations in structural and functional plasticity. These ﬁndings led us to
investigate the role of L-lactate as a potential novel antidepressant. Here we show that peripheral administration of L-lactate
produces antidepressant-like effects in different animal models of depression that respond to acute and chronic antidepressant
treatment. The antidepressant-like effects of L-lactate are associated with increases in hippocampal lactate levels and with changes
in the expression of target genes involved in serotonin receptor trafﬁcking, astrocyte functions, neurogenesis, nitric oxide synthesis
and cAMP signaling. Further elucidation of the mechanisms underlying the antidepressant effects of L-lactate may help to identify
novel therapeutic targets for the treatment of depression.
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INTRODUCTION
Over the past years, evidence has accumulated indicating that glial
cells are involved in the pathophysiology of major depression. In
particular, reductions in the number and density of glial cells have
been observed in different frontolimbic brain regions of depressed
patients.1 Decreases in glial cell density are accompanied by changes
in the expression of several astrocytic markers in frontolimbic cortical
regions and subcortical brain areas including the hippocampus of
depressed patients, suggesting that astrocyte dysfunction contri-
butes to the pathogenesis of major depressive disorder.1,2
Astrocytes are support cells necessary to ensure neuronal
functioning and viability. In this context, astrocytes are involved in
essential brain mechanisms and functions including energy
metabolism, K+ buffering, neurotransmitter recycling, neurogen-
esis, neuronal plasticity and synaptic transmission.3,4 With regard
to energy metabolism, astrocytes have a central role in brain
energy production, delivery, utilization and storage. In particular,
astrocytes respond to glutamatergic activation by increasing the
rate of glucose utilization and the release of lactate,5 a metabolic
substrate that can support neuronal energy demands. Another
metabolic feature of astrocytes with respect to glucose metabo-
lism is that they are the only brain cell type capable of storing
glucose as glycogen. Of particular relevance to depression,
astrocyte glycogen levels are regulated by noradrenaline and
serotonin.6 In addition to fulﬁlling the metabolic needs of
astrocytes,7 astrocytic glycogen breakdown typically results in
the production and release of lactate,7 which can sustain neuronal
function and viability. Taken together, these ﬁndings establish that
both glycogen mobilization and increased glycolysis lead to the
production and release of lactate by astrocytes, highlighting the
important role of this monocarboxylate in brain energetics.
In addition to its role as a neuronal energy substrate, an increasing
number of studies indicate that lactate fulﬁlls a signaling role in the
brain (for review see Mosienko et al.8). For instance, studies have
shown that the transfer of lactate from astrocytes to neurons is
necessary for long-term memory formation9 and for cocaine-
induced long-lasting behavioral effects.10 Interestingly, the role of
lactate in these synaptic plasticity mechanisms is independent of its
function as an energy source.
Analysis of the molecular mechanisms underlying the role of
lactate in synaptic plasticity has revealed that L-lactate increases the
expression of plasticity-related genes including Arc, c-Fos, Zif268 and
BDNF in cortical neurons.11 Interestingly, evidence indicates that
these synaptic plasticity genes are involved in the pathophysiology
and treatment of depression. For instance, the expression of Arc and
Zif268 is decreased in the prefrontal cortex of depressed subjects
and in the medial prefrontal cortex of mice subjected to chronic
social defeat stress.12 In addition, the expression of Zif268 and c-fos is
regulated by different classes of antidepressants in several brain
areas.13,14 Post-mortem analysis of brain-derived neurotrophic factor
expression has shown increased levels in the rodent hippocampus
and in the hippocampus of depressed subjects following anti-
depressant administration.15,16
Studies in humans and animal models have shown that
depression and chronic stress are associated with alterations in
synaptic plasticity that are characterized by a decreased number
of axospinous synapses and by a reduced expression of synapse-
related genes in the prefrontal cortex and hippocampus.17,18
Growing evidence also indicates that reversal of synaptic
deﬁcits by antidepressants involves enhanced expression of
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plasticity-related genes.17 Collectively, these observations led us to
hypothesize that, by increasing the expression of plasticity-related
genes, L-lactate may produce antidepressant-like effects.
The aim of this study was to examine the effects of peripheral
L-lactate administration on depressive-like behavior. Here we
show that acute and chronic peripheral administration of L-lactate
produces antidepressant-like effects. At the cellular level, periph-
eral L-lactate administration increases hippocampal extracellular
L-lactate levels and regulates downstream signaling molecules and
target genes that may contribute to its antidepressant action.
MATERIALS AND METHODS
Methods not described here can be found in Supplementary Information.
Forced swim test
The forced swim test (FST) was performed as described previously.19 Brieﬂy,
C57Bl/6 mice were placed in a 5 L cylindrical container ﬁlled to a depth of
15 cm with water (23–25℃). A 10 min swim test session was videotaped,
and time spent immobile (deﬁned as minimal movements necessary to stay
aﬂoat) was scored by an individual blind to the drug treatment. Time spent
immobile during the swim session was scored during 4 min after the initial
2 min. Mice were intraperitoneally injected with vehicle (0.9% NaCl), L-lactate
(1 g kg−1), D-lactate (1 g kg−1) or desipramine (20 mg kg−1) and tested 1 h
later. The treatments were randomly assigned.
Repeated open-space FST
The repeated open-space FST was performed as described previously.20
Swimming was carried out for 15 min per session in rat cages (43 L×22 W×23
H, in cm) ﬁlled with water to a depth of 15 cm at 34±1 °C. Mice swam
individually for 15 min per day on 4 consecutive days before intraperitoneal
administration of vehicle (0.9% NaCl), L-lactate (1 g kg−1), D-lactate (1 g kg−1)
or desipramine (20 mg kg−1) and then two times a week until ~3 weeks had
passed. Mice were allocated into the four experimental groups after the fourth
day of pretest. Animals with a decreased immobility time during the pretest
were excluded (two animals). Water was changed after three mice had swum
to maintain a constant water temperature. Swim sessions were videotaped
from above and immobility was scored by an individual blind to the drug
treatment. Immobility was deﬁned as the absence of movements, except
those necessary to keep the head above water.
Corticosterone treatment
An emulsion of corticosterone (4 mg ml− 1) was prepared by mixing
corticosterone with 2% dimethyl sulfoxide (DMSO) in sesame oil. Mice
received a single subcutaneous injection of corticosterone (20 mg kg− 1;
Zhao et al.21) or vehicle (2% DMSO in sesame oil) on each of every 21
consecutive days. In addition, corticosterone-treated mice were given
intraperitoneal injections of vehicle (0.9% NaCl), L-lactate (1 g kg− 1),
D-lactate (1 g kg− 1) or desipramine (20 mg kg− 1) daily for 21 days. The
treatments were randomly assigned. At 24 h after the last injection, mice
were tested in the FST (see above), tail suspension test and saccharin
preference test. For the tail suspension test, mice were individually
suspended by the tip of the tail with an adhesive tape on an horizontal
metal bar at a height of ~ 34 cm. Mice were videotaped during 5 min and
total immobility time was manually recorded. For the saccharin preference
test, mice were singly housed in standard cages 24 h after the last drug
administration. Testing was initiated by presenting two bottles (rando-
mized to right versus left): one ﬁlled with water and the other one with a
0.02% saccharin solution. Bottles were weighed before and 48 h after
saccharin access. Total consumption was calculated and data were
expressed as the percentage of saccharin preference (ratio of the volume
of saccharin consumed to the total volume of ﬂuid consumed).
RESULTS
Increased hippocampal lactate levels after peripheral L-lactate
administration
As an initial step in assessing the potential antidepressant effects
of lactate, we established that peripheral lactate administration
increased lactate concentration in the hippocampus, a key limbic
structure implicated in the pathophysiology of major depression.
Intraperitoneal injection of L-lactate (1 g kg− 1), the physiological
enantiomer of lactate, induced a rapid and sustained increase in
blood lactate level that reached a plateau 5 min after injection and
returned to near-baseline levels within 30 min (Figure 1a). The
maximum increase in blood lactate concentration is within the
same range of blood lactate levels measured in rodents during
exercise.22,23 Using an L-lactate selective biosensor inserted within
the hippocampus, we found that intraperitoneal L-lactate admin-
istration resulted in a signiﬁcant increase of ~ 200 μM in
extracellular lactate concentration that slowly declined to
~ 100 μM within 35 min (Figure 1b). The rapid and transient
elevation of extracellular lactate concentration following vehicle
injection (phase 1; Figure 1b), which is not statistically different
from that induced by L-lactate (phase 1; Figure 1c), is likely to be
Figure 1. Peripheral administration of L-lactate increases extracellular
L-lactate concentration in the hippocampus. (a) Intraperitoneal
injection of L-lactate (1 g kg−1) increases blood lactate concentration.
Data are the mean± s.e.m., n=5 mice per group. (b) Intraperitoneal
L-lactate administration results in a signiﬁcant elevation of hippocam-
pal extracellular L-lactate concentration during phase 2, as measured
with an L-lactate biosensor inserted within the hippocampus. Results
are the mean± s.e.m., n=5 mice per group. (c) Data in (b) expressed as
area under the curve during phases 1 and 2. *Po0.05 compared with
vehicle-treated mice (Student’s t-test).
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caused by injection stress as it has been shown that stress increases
extracellular lactate levels in rodent hippocampus.24,25 However, a
signiﬁcant elevation of hippocampal extracellular lactate concentra-
tion was observed during phase 2 following peripheral L-lactate
administration compared with vehicle injection (Figures 1b and c).
Antidepressant-like effects induced by acute administration of
L-lactate
The effect of peripheral L-lactate administration on depressive-like
behavior was assessed in animal models that respond to both
acute and chronic antidepressant treatment. The effect of
peripheral administration of L-lactate was ﬁrst measured using
the FST, a well-established behavioral despair paradigm used to
screen compounds for putative antidepressant activity.26 A single
peripheral injection of L-lactate (1 g kg− 1, intraperitoneally)
reduced immobility in the FST to a similar extent as desipramine
(Figure 2a), whereas the enantiomer D-lactate had no effect
(Supplementary Figure 1a). Importantly, mice injected with
L-lactate did not display alterations in locomotor activity and
neuromuscular strength as shown in the open-ﬁeld and grip
strength tests (Supplementary Figure 2). Collectively, these data
indicate that acute peripheral administration of L-lactate produces
an antidepressant-like behavioral response in the FST.
Regulation of signaling molecules and target genes by acute
L-lactate administration
As a ﬁrst step towards elucidating how L-lactate induces
antidepressant-like behavior, we sought to identify the signaling
pathways and target genes that are regulated in the hippocampus
after a single peripheral administration of L-lactate.
Because glycogen synthase kinase-3 (GSK3) is implicated in the
etiology and treatment of mood disorders,27 we examined the effect
of L-lactate on phosphorylation level of GSK3. Phosphorylation levels
of both GSK3α and GSK3β in the hippocampus were reduced 1 h
after a single intraperitoneal injection of L-lactate (1 g kg−1)
(Figures 2b and c). Accumulating evidence also supports a role of
the transcription factor cAMP response element-binding protein
(CREB) in the pathophysiology and treatment of depression.28 We
therefore examined whether L-lactate regulates the phosphorylation
level of CREB at Ser133. A single peripheral L-lactate administration
was found to reduce phospho-CREB levels in the hippocampus 1 h
after injection (Figure 2d).
To further characterize the molecular mechanisms of L-lactate
action, we sought to identify target genes that are rapidly
regulated by L-lactate in the hippocampus. We observed that a
single peripheral injection of L-lactate upregulates the expression
of Arc mRNA in the hippocampus (Figure 2e). Because previous
studies suggest that inﬂammation increases the risk of developing
major depression,29 we examined whether L-lactate regulated the
expression of cyclooxygenase-2 (COX-2), an enzyme responsible
for the formation of prostaglandins. Mice that received a single
intraperitoneal injection of L-lactate showed a decreased expres-
sion of COX-2 mRNA in the hippocampus (Figure 2f). Earlier
studies have shown that inhibition of nitric oxide synthase or NO
production induces antidepressant-like effects in the FST.30 In this
context, we determined whether L-lactate regulated the expres-
sion of nitric oxide synthase 1 (NOS1), the neuronal isoform of
NOS. We found that NOS1 mRNA levels were decreased in the
hippocampus of mice that received 1 h earlier a single peripheral
administration of L-lactate (Figure 2g).
Antidepressant-like effects produced by chronic L-lactate
administration
We further investigated the antidepressant-like behavioral
effects of L-lactate in the corticosterone model of depression.
Previous studies have reported that chronic administration of
corticosterone in rodents produces behavioral and neurobiologi-
cal alterations that mimic symptoms and neurobiological changes
associated with human depression.31 We therefore examined the
effect of L-lactate on depressive-like behavior induced by chronic
administration of corticosterone. Similarly to desipramine, we
found that chronic administration of L-lactate (Figures 3a and b),
but not D-lactate (Supplementary Figure 1b), abolished the
increased immobility induced by corticosterone treatment in the
FST and tail suspension test. In rodents, chronic corticosterone
exposure induces anhedonia, a core symptom of depression.31
Therefore, we investigated whether L-lactate reversed the
anhedonic-like behavior induced by chronic corticosterone treat-
ment. Our data revealed that chronic peripheral administration
of L-lactate reversed the corticosterone-induced decrease in
saccharin consumption (Figure 3c).
Finally, the effect of peripheral L-lactate administration on
depressive-like behavior was investigated in the the open-space
forced swim model of depression. This behavioral paradigm
induces a chronic depression-like state that responds to chronic
but not acute antidepressant treatment.20,32 Daily injection of
L-lactate for 3 weeks decreased the immobility time in the open-
space forced swim model of depression to a similar extent as
desipramine (Figure 4a). In contrast to L-lactate, chronic admin-
istration of D-lactate did not reduce the immobility time in this
behavioral model of depression (Supplementary Figure 1c).
Analysis of target genes regulated by chronic L-lactate
administration
Characterization of the molecular mechanisms underlying the
chronic antidepressant-like effects of L-lactate revealed that
chronic peripheral administration of L-lactate regulated the
expression of a speciﬁc group of genes involved in major
depression and antidepressant treatment. Thus, chronic peripheral
L-lactate administration increased mRNA and protein levels
encoding the regulator of serotonin receptors p11,33 the astrocytic
marker S100β1 and the transcription factor Hes534 in the
hippocampus of animals subjected to the open-space FST
compared with vehicle-treated animals (Figures 4b–d).
In addition to p11, S100β and Hes5, the expression of cAMP-
speciﬁc phosphodiesterase-4D (PDE4D) and NOS1 was found to be
decreased by chronic peripheral administration of L-lactate both at
the mRNA and protein levels in the hippocampus of animals
subjected to the open-space FST compared with vehicle-treated
animals (Figures 4e and f). Although NOS1AP mRNA levels were
decreased by chronic L-lactate administration, NOS1AP expression at
the protein level remained unaltered (Figure 4g).
DISCUSSION
The present set of data shows that peripheral administration of L-
lactate produces antidepressant-like effects in different animal
models of depression that respond to acute or chronic antidepres-
sant treatment. In particular, chronic peripheral L-lactate administra-
tion completely reverses the corticosterone-induced anhedonia-like
behavior (Figure 3c) and partially restores mobility in the open-space
forced swim model of depression (Figure 4a). Importantly, these
antidepressant effects of L-lactate, that are similar to those induced
by desipramine, are not reproduced by the enantioner D-lactate
(Supplementary Figure 1) and do not result from changes in
locomotor activity and muscle strength (Supplementary Figure 2).
Acute peripheral administration of L-lactate increases hippo-
campal extracellular lactate concentration (Figure 1b) and
regulates downstream signaling proteins (Figures 2b–d) and
target genes (Figures 2e–g) in the hippocampus. The elevated
hippocampal lactate concentration following acute peripheral
lactate administration (Figure 1b) is consistent with previous data
showing that a net uptake of lactate into the human brain is
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observed when arterial lactate levels increase such as during
lactate infusion or intense exercise.35,36
Among the genes regulated by a single peripheral injection of
L-lactate (Figures 2e–g), Arc is important for synaptic function and
dysregulation of Arc expression may lead to cognitive disorders.37
Recent data from our laboratory have shown that L-lactate
increases the expression of synaptic plasticity-related genes
including Arc, c-fos and Zif268 in cortical neurons.11 With regard
to major depression, the expression of Arc is decreased in the
prefrontal cortex of depressed subjects and in the medial
prefrontal cortex of mice susceptible to chronic social defeat
stress.12 Conversely, chronic antidepressant administration and
electroconvulsive stimulation upregulate Arc mRNA expression in
the hippocampus and parietal cortex.38 In addition, administration
of the fast-acting antidepressant ketamine induces Arc expression
in the rat prefrontal cortex and other cortical regions.39 These
Figure 2. L-Lactate induces antidepressant-like effects in the forced swim test and regulates downstream signaling and target genes. (a) Acute
peripheral administration of L-lactate produces antidepressant-like effects in the forced swim test (FST). Mice received a single intraperitoneal
injection of vehicle (0.9% NaCl, n= 17), L-lactate (1 g kg− 1, n= 17) or desipramine (20 mg kg− 1, n= 12) and were subjected to behavioral
testing 1 h later. Both L-lactate and desipramine signiﬁcantly reduced immobility in the FST as analyzed by one-way analysis of variance
(ANOVA), followed by Tukey's post hoc test (F2,4= 6.564, Po0.05). Data are the mean± s.e.m. **Po0.01 compared with vehicle-treated mice.
(b–d) Phosphorylation levels of glycogen synthase kinase-3α (GSK3α), GSK3β and cAMP response element-binding protein (CREB) in the
hippocampus were reduced 1 h after a single intraperitoneal injection of L-lactate, as shown by western blot analysis. Data are the mean± s.e.
m., n= 10 mice per group. *Po0.05 compared to vehicle-treated mice (Student’s t-test). (e–g) Quantitative PCR analysis revealed that a single
intraperitoneal injection of L-lactate regulated the expression of Arc, cyclooxygenase-2 (COX-2) and nitric oxide synthase 1 (NOS1) mRNAs. Arc
mRNA level was increased in the hippocampus of L-lactate- compared with vehicle-treated mice. COX-2 and NOS1 mRNA levels were
decreased in the hippocampus of L-lactate- compared with vehicle-treated mice. Data are the mean± s.e.m. (vehicle n= 16, L-lactate n= 17).
*Po0.05 compared with vehicle-treated mice (Student’s t-test).
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ﬁndings support the view that the expression of Arc is down-
regulated in depressive-like states in human and rodents and is
upregulated following antidepressant treatment. In line with this
view, the increased expression of Arc in the hippocampus
following a single injection of L-lactate (Figure 2e) is likely to be
implicated in the acute antidepressant-like effects of L-lactate.
Previous studies indicate that inﬂammatory processes may be
involved in patients suffering from major depression. As proin-
ﬂammatory cytokines and tumor necrosis factor-α production is
increased in depressed patients,40 anti-inﬂammatory treatment
should reduce depressive symptoms. In this regard, treatment
with the COX-2 inhibitor celecoxib decreases depressive symp-
toms in depressed patients.41 In rodents, chronic treatment with
celecoxib reverses chronic unpredictable stress-induced depres-
sive-like behavior through reduction of COX-2 expression.42
Collectively, these data suggest that the decreased expression of
COX-2 by L-lactate in the hippocampus (Figure 2f) may contribute
to the acute antidepressant actions of L-lactate.
Increasing evidence indicates that inhibition of NOS induces
antidepressant-like effects.43 In particular, pharmacological inhibi-
tion of NOS1 produces antidepressant-like effects in the FST30 and
chronic unpredictable mild stress.44 Inhibition of NOS1 expression
in the hippocampus following acute (Figure 2g) and chronic
administration of L-lactate (Figure 4f) is consistent with these
ﬁndings and suggests that the decreased expression of NOS1 is
important in mediating the acute and chronic antidepressant-like
effects of L-lactate.
Previous studies have provided evidence that dysregulation of
GSK3 promotes susceptibility to mood disorders and that inhibition
of GSK3 activity reduces depression- and manic-like behaviors.27
Interestingly, inhibition of GSK3 phosphorylation by a single
administration of L-lactate (Figures 2b and c) contrasts with the
acute effect of the antidepressant ﬂuoxetine that increases GSK3
phosphorylation in the prefrontal cortex and hippocampus.45
The transcription factor CREB is involved in the pathophy-
siology of depression and its treatment by antidepressants.28 Most
studies have shown that CREB expression and activity are
increased by chronic treatment with antidepressants in rodents
and post-mortem human brain.46,47 However, acute administra-
tion of antidepressants does not affect CREB phosphorylation in
the hippocampus.48 Interestingly, electroconvulsive shocks, a
therapy used for severely depressed patients, activates protein
phosphatase 2A and reduces GSK3β and CREB phosphorylation,49
similarly to what was observed after a single administration of
L-lactate (Figures 2c and d).
P11 was initially identiﬁed as a binding protein for 5-HTR1B,
5-HTR1D and 5-HTR4 and overexpression of p11 was shown to
increase 5-HTR1B and 5-HTR4 expression at the cell surface, thereby
amplifying 5-HT signaling.33 Levels of P11 are decreased in the
anterior cingulate cortex and nucleus accumbens of depressed
patients as well as in a genetic animal model of depression.33
Conversely, antidepressants from different classes and electrocon-
vulsive therapy increase p11 levels in the frontal cortex and
hippocampus of rodents.33 The increased expression of p11 by L-
lactate in the hippocampus of animals subjected to the open-space
FST (Figure 4b) is consistent with these studies and supports a role
for p11 in the chronic antidepressant-like effects of L-lactate.
Although brain imaging and post-mortem studies have
identiﬁed changes in the number and shape of speciﬁc neuronal
populations in the brain of depressed patients, abundant evidence
indicates that structural and functional abnormalities of astrocytes
have a major role in the development of depression.1 In particular,
human post-mortem studies have revealed alterations in the
expression of astrocyte markers in different frontolimbic brain
regions.1 Among astrocyte markers, the expression of the calcium-
binding protein S100β is reduced in the ventral prefrontal cortex
of depressed suicides50 and the density of S100β-immunopositive
astrocytes is decreased in the CA1 pyramidal layer of depressed
subjects.51 In contrast, chronic treatment with the selective
serotonin reuptake inhibitor antidepressant ﬂuoxetine increases
S100β expression in the rodent hippocampus.52,53 Our data
showing that L-lactate administration increases S100β expression
in the hippocampus of animals subjected to the open-space FST
(Figure 4c) are in line with these observations, and suggest that
S100β may be a mediator of the chronic antidepressant-like
effects of L-lactate.
Hes5 is a downstream effector of Notch signaling, a pathway
that has a central role in regulating hippocampal
neurogenesis.54,55 Stress, a major risk factor for depression,
decreases hippocampal neurogenesis, whereas chronic antide-
pressant treatment normalizes neurogenesis.56 The increased
expression of Hes5 by L-lactate (Figure 4d) in the hippocampus
of animals subjected to the open-space FST suggests that
Figure 3. Chronic peripheral administration of L-lactate produces antidepressant-like effects in the chronic corticosterone paradigm. Mice
received a single subcutaneous injection of corticosterone (20 mg kg− 1) or vehicle (2% dimethyl sulfoxide (DMSO) in sesame oil) on each of 21
consecutive days. Corticosterone-treated mice were given intraperitoneal injections of vehicle (0.9% NaCl), L-lactate (1 g kg− 1) or desipramine
(20 mg kg− 1) daily for 21 days. At 24 h after the last injection, mice were tested in the forced swim test (FST), tail suspension test (TST) and
saccharin preference test (SPT). (a and b) Chronic administration of L-lactate and desipramine (n= 9 and n= 10, respectively) abolished the
increased immobility induced by corticosterone treatment in the FST (F3,45= 15.041) and TST (F3,45= 14.253). (c) Chronic peripheral
administration of L-lactate reversed the corticosterone-induced decrease in saccharin preference (F3,33= 4.436). Data are the mean± s.e.m.
One-way analysis of variance (ANOVA) followed by Tukey's post hoc test. **Po0.01 and *Po0.05 compared with vehicle + vehicle-treated
mice (n= 10); ##Po0.01 and #Po0.05 compared with corticosterone + vehicle-treated mice (n= 8).
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stimulation of hippocampal neurogenesis may be involved in the
chronic antidepressant-like effects of L-lactate.
Several lines of evidence suggest that dysregulation of cAMP-
mediated signaling is involved in the pathophysiology of
depression. Thus, elevation of intracellular cAMP via pharmacolo-
gical inhibition of PDE4 enzymes induces antidepressant-like
effects in animal models.57,58 Further studies have shown that the
PDE4D subtype has a pivotal role in the antidepressant-like effects
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of PDE4 inhibitors. Thus, mice lacking PDE4D59 or with reduced
expression of PDE4D in the prefrontal cortex60 exhibit
antidepressant-like behavior. The inhibitory effect of L-lactate on
the expression of PDE4D in the hippocampus of animals subjected
to the open-space FST (Figure 4e) is consistent with these ﬁndings
and suggests that reduction of PDE4D expression may contribute
to the chronic antidepressant-like effects of L-lactate.
Collectively, data regarding the characterization of the molecular
mechanisms underlying the chronic antidepressant effects of
L-lactate show that L-lactate acts by regulating the expression of
proteins involved in 5-hydroxytryptamine receptor trafﬁcking,
astrocyte functions, neurogenesis, NO synthesis and cAMP signaling.
Taken together, these studies identify a previously unrecog-
nized action of L-lactate by which acute and chronic peripheral
administration produces antidepressant-like behavioral responses.
Peripheral L-lactate injection increases hippocampal lactate levels
and regulates downstream signaling molecules and target genes
that may contribute to the antidepressant action of L-lactate.
Further elucidation of the mechanisms underlying the antide-
pressant effects of L-lactate may help to identify novel therapeutic
targets for the treatment of depression.
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